BSD Medical Corporation (BSDM)’s Investor and Analyst Conference Call Transcript

Second, this may be very technical and tactical, so we are changing and have changed fiscal year to go from January to December, so as we participate in this call we are in the second week of 2015 and bill will walk through with you our reported schedule but it will be in accordance with a calendar year we’ll wind up our fiscal year. The reason that is important is there is a buying cycle for hospitals and for physicians. They are more closely aligned with the January to December time frame and for the quarterly filings that we will be part of public companies to follow. That will align the organization and the urgency for top line sales in line with how our competitors sell and how our customers buy.

Third, we have made the decision to exit hypothermia in 2015. I recognize and received passionate emails from many shareholders about the value of that business both clinically as well as the potential for it financially. Both products as I mentioned microwave ablation, hypothermia do wonderful things, for patients and unfortunately, we are in a resource situation where two very different products where we made the decision to go forward with microwave ablation and Bill and I are working with various parties to divest the hypothermia business and set that business up for success. Either way, we have made the decision to exit hypothermia in 2015.

The words that I had prepared for the launch of the sales program as you get to know me you will find that we will operate with offensive urgency. The first week of January we had our global sales team in, are now working with our distribution partners and we have launched to them the new sales programs, that will give more flexibility to customers to buy the product whether they want to invest from a capital stand point have an up charge on our incentive, or to have flexibility for BSD to participate in the buying cycle with them.